NLSP 5.29 NLS Pharmaceutics AG
| Range: | 4.08-30.0 | Vol Avg: | 70573 | Last Div: | 0 | Changes: | 0.26 |
| Beta: | -0.58 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jan 29 2021 | Empoloyees: | 6 | ||
| CUSIP: | H57830103 | CIK: | 0001783036 | ISIN: | CH0523961370 | Country: | CH |
| CEO: | Mr. Alexander Zwyer M.B.A. | Website: | https://nlspharma.com | ||||
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow